First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer

Trial StartTLX597-TxPositive

AI Analysis

Summary

Telix Pharmaceuticals announced first patient dosing in the OPTIMAL-e trial for TLX597-Tx, a radiopharmaceutical targeting metastatic hormone-sensitive prostate cancer, led by Professor Louise Emmett at St Vincent's Hospital in Sydney, Australia.

Clinical Trial Data

Outcome Details

First patients dosed in OPTIMAL-e trial

Importance:5/10

Sentiment:

0.60

prostate cancerradiopharmaceuticalclinical trialtrial initiationTLX597-Tx

Related Companies

$TLX

Read the original article

Published by GlobeNewswire Clinical Studies on July 15, 2026 8:20 PM

Read Original